The International Myeloma Working Group (IMWG) has published a consensus statement providing recommendations for the best use of 18-fluorodeoxyglucose (18F-FDG) PET/CT in the diagnosis and management of myeloma patients. Published in the Lancet Oncology, they consider this technique to be valuable not only in the initial work up for newly diagnosed myeloma patients but also for relapsed or refractory myeloma patients. They also recommend that 18F-FDG PET/CT should be mandatory to confirm a suspected diagnosis of solitary plasmacytoma when whole body MRI is unavailable or is negative. However, they suggest that the major strength of 18F-FDG PET/CT is in the evaluation and monitoring of response to treatment and therefore the imaging tool of choice for detecting minimal residual disease (MRD).